TrialReader


Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.

NCT03232632 — Early Phase 1, Terminated, 7 participants, University Hospital, Toulouse

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Assessment of Cardiac Fixation During Positron Emission Tomography (PET) Examination Using 18F-Flutemetamol (Vizamyl ®) Within Amyloid Cardiac Injuries.

RegistryNCT03232632, acronym AMYLCAR
StatusTerminated - intervention programming
PhaseEarly Phase 1
Study typeInterventional; na, single group, masking: none, supportive care
Enrollment7 (Actual)
SponsorUniversity Hospital, Toulouse (Other)
ConditionsCardiac Amyloidosis
InterventionsPET with 18 F-Flutemetamol (Drug)
Datesstart 2017-03-15, primary completion 2019-09-15, completion 2019-09-15, first posted 2017-07-28, last updated 2020-08-26
Locations1 site in France

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Cardiac Amyloidosis All trials of PET with 18 F-Flutemetamol

-Summary

To estimate distribution's parameters of 18F-Flutemetamol (Vizamyl®) fixation on myocardium for patients with amyloid cardiac injuries.

Expand all sections  ·  Collapse all

+Detailed description

Hypothesis had been performed that PET with 18F-Flutemetamol (Vizamyl®) could lead an early diagnostic. Indeed, this tracer had been recently used to highlight inter-cerebral beta-amyloid plaques on patients with Alzheimer Disease.

Because this labelling is performed on amyloid deposits, this tracer would lead to view and to quantify amyloid deposits within cardiac amyloid injuries.

Results of this PET will be combined with scan examinations for a better anatomic tracking.

+Arms and interventions

ArmTypeInterventionsDescription
PET with 18 F-FlutemetamolExperimentalDrug: PET with 18 F-FlutemetamolPET with 18 F-Flutemetamol (Vizamyl®) = product under Alzheimer's disease indication
  • PET with 18 F-Flutemetamol (Drug), also known as Vizamyl®: PET with 18 F-Flutemetamol (Vizamyl ®)

+Outcome measures

Primary outcomes

  • ratio Heart/ Upper Mediastinum [average of last 15 minutes]: peak of 18F-Flutemetamol capture
  • standardized uptake value (SUV) measures [average of last 15 minutes]: standardized uptake value (SUV) measures

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Patients followed for amyloidosis with proved cardiac injury or strongly suspected:

  * cardiac echography with typical signs of amyloid injury,
  * anatomical result confirming presence of amyloid deposits at cardiac or peripheral level
* Signature of Informed Consent Form,
* Affiliation to a social security system

Exclusion Criteria:

* Patient who suffers from another pathology which could lead cardiac injury (coronary disease, valvular disease, other pathology of deposit),
* Pregnancy and lactating women,
* Absence of effective contraception,
* Irradiating examination performed within the last 12 months or scheduled within the next 12 months,
* Unable patient physically, mentally or legally to provide informed consent,
* Patient under a system of legal protection

+Locations (1)

FacilityCityCountryStatus
University Hospital ToulouseToulouseFrance

+Investigators

  • Eric OUHAYOUN, MD, Principal investigator, University Hospital, Toulouse

My Notes